

Janet Hardy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7720885/publications.pdf>

Version: 2024-02-01

98
papers

2,532
citations

186265

28
h-index

206112

48
g-index

107
all docs

107
docs citations

107
times ranked

2489
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical practice guidelines for communicating prognosis and end-of-life issues with adults in the advanced stages of a life-limiting illness, and their caregivers. Medical Journal of Australia, 2007, 186, S77-S105.	1.7	254
2	Fatigue in patients with cancer. European Journal of Cancer, 1998, 34, 1670-1676.	2.8	217
3	Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Toxicity of Subcutaneous Ketamine in the Management of Cancer Pain. Journal of Clinical Oncology, 2012, 30, 3611-3617.	1.6	189
4	What influences participation in clinical trials in palliative care in a cancer centre?. European Journal of Cancer, 2000, 36, 621-626.	2.8	118
5	A prospective survey of the use of dexamethasone on a palliative care unit. Palliative Medicine, 2001, 15, 3-8.	3.1	111
6	Double-Blind, Placebo-Controlled, Randomized Trial of Octreotide in Malignant Bowel Obstruction. Journal of Pain and Symptom Management, 2015, 49, 814-821.	1.2	83
7	The use of the Edmonton Symptom Assessment Scale (ESAS) within a palliative care unit in the UK. Palliative Medicine, 1998, 12, 75-82.	3.1	80
8	What do palliative care patients and their relatives think about research in palliative care?â€”a systematic review. Supportive Care in Cancer, 2010, 18, 905-911.	2.2	80
9	A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24Âmg p.o. with placebo and metoclopramide 10Âmg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Supportive Care in Cancer, 2002, 10, 231-236.	2.2	64
10	Pharmacological options for the management of refractory cancer painâ€”what is the evidence?. Supportive Care in Cancer, 2015, 23, 1473-1481.	2.2	53
11	Treatment of Nausea and Vomiting in Terminally Ill Cancer Patients. Drugs, 2008, 68, 2575-2590.	10.9	52
12	<i>CYP2B6</i> allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. British Journal of Clinical Pharmacology, 2015, 80, 276-284.	2.4	51
13	The Efficacy of Haloperidol in the Management of Nausea and Vomiting in Patients with Cancer. Journal of Pain and Symptom Management, 2010, 40, 111-116.	1.2	50
14	The value of computed tomographic (CT) scan surveillance in the detection and management of brain metastases in patients with small cell lung cancer. British Journal of Cancer, 1990, 62, 684-686.	6.4	47
15	Novel consent process for research in dying patients unable to give consent. BMJ: British Medical Journal, 2003, 327, 198-0.	2.3	46
16	Randomised controlled trials of palliative care â€” a survey of the views of advanced cancer patients and their relatives. European Journal of Cancer, 2008, 44, 1820-1828.	2.8	43
17	Corticosteroids for the management of cancer-related pain in adults. The Cochrane Library, 2021, 2021, CD010756.	2.8	43
18	The Effect of Methylphenidate on Fatigue in Advanced Cancer: An Aggregated N-of-1 Trial. Journal of Pain and Symptom Management, 2015, 50, 289-296.	1.2	40

#	ARTICLE	IF	CITATIONS
19	Neuropathic pain in cancer: systematic review, performance of screening tools and analysis of symptom profiles. <i>British Journal of Anaesthesia</i> , 2017, 119, 765-774.	3.4	38
20	Outcome of Malignant Spinal Cord Compression at a Cancer Center. <i>Journal of Pain and Symptom Management</i> , 2000, 19, 257-264.	1.2	35
21	Interventional options for the management of refractory cancer pain—what is the evidence?. <i>Supportive Care in Cancer</i> , 2016, 24, 1429-1438.	2.2	34
22	An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer. <i>Supportive Care in Cancer</i> , 2005, 13, 715-721.	2.2	33
23	Therapeutic Challenges in Cancer Pain Management: A Systematic Review of Methadone. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2014, 28, 197-205.	0.8	33
24	Opioid addiction and misuse in adult and adolescent patients with cancer. <i>Internal Medicine Journal</i> , 2017, 47, 632-636.	0.8	33
25	Chemoprevention of breast cancer. <i>Breast Cancer Research and Treatment</i> , 1989, 14, 23-31.	2.5	32
26	Designing and conducting randomized controlled trials in palliative care: A summary of discussions from the 2010 clinical research forum of the Australian Palliative Care Clinical Studies Collaborative. <i>Palliative Medicine</i> , 2012, 26, 1042-1047.	3.1	31
27	Placebo and Nocebo Effects in Randomized Controlled Trials: The Implications for Research and Practice. <i>Journal of Pain and Symptom Management</i> , 2013, 46, 722-730.	1.2	31
28	Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD). <i>BMC Palliative Care</i> , 2019, 18, 110.	1.8	31
29	Using National Health Policies to Improve Access to Palliative Care Medications in the Community. <i>Journal of Pain and Symptom Management</i> , 2009, 37, 395-402.	1.2	30
30	Sedation in terminally ill patients. <i>Lancet</i> , The, 2000, 356, 1866-1867.	13.7	29
31	Planning phase III multi-site clinical trials in palliative care: the role of consecutive cohort audits to identify potential participant populations. <i>Supportive Care in Cancer</i> , 2010, 18, 1571-1579.	2.2	24
32	A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment. <i>BMC Cancer</i> , 2018, 18, 510.	2.6	22
33	An Open-Label Pilot Study Testing the Feasibility of Assessing Total Symptom Burden in Trials of Cannabinoid Medications in Palliative Care. <i>Journal of Palliative Medicine</i> , 2020, 23, 650-655.	1.1	22
34	Defining Refractory Pain in Cancer for Clinicians and Researchers. <i>Journal of Palliative Medicine</i> , 2012, 15, 5-6.	1.1	21
35	Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). <i>Trials</i> , 2020, 21, 611.	1.6	21
36	Can the LANSS scale be used to classify pain in chronic cancer pain trials?. <i>Supportive Care in Cancer</i> , 2013, 21, 3387-3391.	2.2	20

#	ARTICLE	IF	CITATIONS
37	Overcoming barriers to evidence-based patient blood management: a restricted review. <i>Implementation Science</i> , 2020, 15, 6.	6.9	20
38	Quantitative determination of the enantiomers of methadone in human plasma and saliva by chiral column chromatography coupled with mass spectrometric detection. <i>Talanta</i> , 2016, 149, 142-148.	5.5	19
39	Consent for trials in palliative care. <i>Lancet, The</i> , 2000, 356, S44.	13.7	16
40	Gatekeeping from palliative care research trials. <i>Progress in Palliative Care</i> , 2008, 16, 167-171.	1.2	16
41	Saliva versus Plasma for Pharmacokinetic and Pharmacodynamic Studies of Fentanyl in Patients with Cancer. <i>Clinical Therapeutics</i> , 2015, 37, 2468-2475.	2.5	16
42	Assessing quality of life in palliative care settings: head-to-head comparison of four patient-reported outcome measures (EORTC QLQ-C15-PAL, FACT-Pal, FACT-Pal-14, FACT-G7). <i>Supportive Care in Cancer</i> , 2020, 28, 141-153.	2.2	16
43	Emotionally reflexive labour in end-of-life communication. <i>Social Science and Medicine</i> , 2021, 291, 112928.	3.8	14
44	Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer?. <i>Supportive Care in Cancer</i> , 2012, 20, 767-772.	2.2	13
45	A randomised, double-blind controlled trial of intranasal midazolam for the palliation of dyspnoea in patients with life-limiting disease. <i>Supportive Care in Cancer</i> , 2016, 24, 3069-76.	2.2	13
46	Methotrimeprazine versus haloperidol in palliative care patients with cancer-related nausea: a randomised, double-blind controlled trial. <i>BMJ Open</i> , 2019, 9, e029942.	1.9	13
47	Letter to the editor: Subcutaneous sufentanil for palliative care patients in a hospital setting. <i>Palliative Medicine</i> , 2008, 22, 89-90.	3.1	12
48	Barriers to the Best Care of the Dying in Queensland, Australia. <i>Journal of Palliative Medicine</i> , 2008, 11, 1325-1329.	1.1	12
49	Preliminary Development and Validation of a New End-of-Life Patient-Reported Outcome Measure Assessing the Ability of Patients to Finalise Their Affairs at the End of Life. <i>PLoS ONE</i> , 2014, 9, e94316.	2.5	12
50	Impact of Opioid Therapy on Sleep and Respiratory Patterns in Adults With Advanced Cancer Receiving Palliative Care. <i>Journal of Pain and Symptom Management</i> , 2018, 55, 962-967.	1.2	12
51	An audit of morphine prescribing in a specialist cancer hospital. <i>Palliative Medicine</i> , 1994, 8, 5-10.	3.1	11
52	Practice review: Evidence-based quality use of corticosteroids in the palliative care of patients with advanced cancer. <i>Palliative Medicine</i> , 2021, 35, 461-472.	3.1	11
53	Lymphoedema - prevention rather than cure. <i>Annals of Oncology</i> , 1991, 2, 532-533.	1.2	10
54	Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?. <i>Supportive Care in Cancer</i> , 2014, 22, 325-330.	2.2	9

#	ARTICLE	IF	CITATIONS
55	Symptom Clusters in Men With Castrate-Resistant Prostate Cancer. <i>Journal of Pain and Symptom Management</i> , 2017, 54, e1-e3.	1.2	9
56	An open-label pilot study of oral vitamin C as an opioid-sparing agent in patients with chronic pain secondary to cancer. <i>Supportive Care in Cancer</i> , 2017, 25, 341-343.	2.2	9
57	<p>Preoperative Anemia and Iron Deficiency Screening, Evaluation and Management: Barrier Identification and Implementation Strategy Mapping</p>. <i>Journal of Multidisciplinary Healthcare</i> , 2020, Volume 13, 1759-1770.	2.7	8
58	Attitudes of Patients with Advanced Cancer Toward Research. <i>Journal of Pain and Symptom Management</i> , 2009, 38, e5-e6.	1.2	7
59	Potential economic impact on hospitalisations of the Palliative Care Clinical Studies Collaborative (PaCCSC) ketamine randomised controlled trial. <i>Australian Health Review</i> , 2016, 40, 100.	1.1	7
60	Prevalence of QTc Prolongation in Patients With Advanced Cancer Receiving Palliative Care—A Cause for Concern?. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 856-863.	1.2	7
61	<p>Preoperative Anemia Screening and Treatment Practices in Patients Having Total Joint Replacement Surgery: A Retrospective, Observational Audit</p>. <i>Journal of Blood Medicine</i> , 2020, Volume 11, 259-265.	1.7	7
62	Palliation of nausea and vomiting. , 2015, , 661-674.		7
63	Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer?. <i>Clinical Therapeutics</i> , 2017, 39, 1840-1848.	2.5	6
64	Assessing transfusion practice in elective surgical patients: a baseline audit. <i>ISBT Science Series</i> , 2019, 14, 415-422.	1.1	6
65	Central Sleep Apnea in Cancer Patients on Opioids. <i>Journal of Pain and Symptom Management</i> , 2010, 40, e3-e5.	1.2	5
66	Reply to K. Jackson et al and W. Leppert. <i>Journal of Clinical Oncology</i> , 2013, 31, 1375-1376.	1.6	5
67	Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 705-713.	2.0	5
68	Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer?. <i>Current Treatment Options in Oncology</i> , 2022, 23, 514-525.	3.0	5
69	Integration of oncology and palliative care: setting a benchmark. <i>Supportive Care in Cancer</i> , 2017, 25, 3253-3259.	2.2	4
70	Quality use of medicines: Oral corticosteroids in advanced cancer. <i>Palliative Medicine</i> , 2019, 33, 1325-1326.	3.1	4
71	Harms From Haloperidol for Symptom Management in Palliative Care—A Post Hoc Pooled Analysis of Three Randomized Controlled Studies and Two Consecutive Cohort Studies. <i>Journal of Pain and Symptom Management</i> , 2019, 58, e6-e8.	1.2	4
72	Acetaminophen in Cancer Pain. <i>Journal of Clinical Oncology</i> , 2005, 23, 1586-1586.	1.6	3

#	ARTICLE	IF	CITATIONS
73	Creating a palliative care research network in Queensland, Australia – is this the answer?. <i>Progress in Palliative Care</i> , 2005, 13, 277-281.	1.2	3
74	Progressing an Evidence-Base Beyond Case Series. <i>Journal of Palliative Medicine</i> , 2011, 14, 1283-1283.	1.1	3
75	Validation of a Fentanyl Transdermal Adhesion Scoring Tool for Use in Clinical Practice. <i>Journal of Pain and Symptom Management</i> , 2015, 49, 934-938.	1.2	3
76	Corticosteroids as Co-analgesics With Opioids for Cancer-Related Pain: A Feasibility Study. <i>Journal of Pain and Symptom Management</i> , 2017, 54, e1-e2.	1.2	3
77	The lipophilic opioids: fentanyl, alfentanil, sufentanil, and remifentanil. , 2009, , 175-192.		3
78	Economic evaluation of the randomised, double-blind, placebo-controlled study of subcutaneous ketamine in the management of chronic cancer pain. <i>Palliative Medicine</i> , 2019, 33, 74-81.	3.1	2
79	Stringent Control of Opioids: Sound Public Health Measures, but a Step Too Far in Palliative Care?. <i>Current Oncology Reports</i> , 2020, 22, 34.	4.0	2
80	The Management of Nausea and Vomiting Not Related to Anticancer Therapy in Patients with Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 17.	3.0	2
81	Opioids in the terminal phase. , 2009, , 455-460.		2
82	Diamorphine. , 2009, , 263-268.		2
83	Association of polymorphisms in <i>ARRB2</i> and clinical response to methadone for pain in advanced cancer. <i>Pharmacogenomics</i> , 2022, 23, 281-289.	1.3	2
84	Can transdermal fentanyl cause diarrhea?. <i>Journal of Pain and Symptom Management</i> , 1997, 13, 188-189.	1.2	1
85	Insurance cover for research in independent hospices. <i>Palliative Medicine</i> , 2003, 17, 648-649.	3.1	1
86	A Theoretically Informed Approach to Support the Implementation of Pre-Operative Anemia and Iron Deficiency Screening, Evaluation, and Management Pathways: Protocol for a Type Two Hybrid-Effectiveness Study. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 1037-1044.	2.7	1
87	Opioids in renal failure. , 2009, , 69-80.		1
88	Opioid rotation. , 2009, , 301-312.		1
89	Palliative medicine in cancer. <i>Lancet, The</i> , 1997, 350, 296.	13.7	0
90	Correspondence. <i>International Journal of Palliative Nursing</i> , 2000, 6, 358-359.	0.5	0

#	ARTICLE	IF	CITATIONS
91	A Review of the COX-2 Inhibitors. Progress in Palliative Care, 2001, 9, 47-52.	1.2	0
92	Palliative care in breast cancer. , 2003, , 357-385.		0
93	Is levomepromazine stable over time?. Palliative Medicine, 2011, 25, 284-285.	3.1	0
94	Castrate-resistant prostate cancer: lessons learnt from a pilot study in the palliative care research population. International Journal of Palliative Nursing, 2018, 24, 96-98.	0.5	0
95	Interests and conflicts when writing, reviewing and editing papers on voluntary assisted dying. Internal Medicine Journal, 2021, 51, 1563-1566.	0.8	0
96	Palliative care in paediatric oncology. , 2004, , 684-703.		0
97	Codeine. , 2009, , 81-88.		0
98	Symptom management in the last days of life. , 2011, , 398-404.		0